STAMPEDE
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
What is the best treatment for people with advanced prostate cancer?
What is this study about?
Prostate cancer accounts for around one fifth of all cancers among men. In the UK there are around 25,000 new cases of prostate cancer each year, and around 10,000 deaths.
Most men are given hormone therapy if their prostate cancer has spread (metastasised), or if the cancer is very likely to spread. This usually stops the tumour from growing for a while. But in most cases, over time, the tumour will start to grow again.
The aim of this trial is to try to prevent tumour re-growth by adding other treatment(s) to the hormone therapy. The trial is currently testing metformin (a drug used to treat type 2 diabetes) and transdermal oestradiol hormone patches (as an alternative way to deliver hormone therapy). Celecoxib, zoledronic acid, docetaxel, abiraterone alone and with enzalutamide, and radiotherapy have previously been tested.
Short films summarising the results so far:
- 2023: STAMPEDE abiraterone and abiraterone + enzalutamide comparisons - a follow-up
- 2018: STAMPEDE M1 radiotherapy comparison results
- 2017: STAMPEDE abiraterone results
- 2015: STAMPEDE docetaxel and zoledronic acid results
2023: STAMPEDE abiraterone and abiraterone + enzalutamide comparisons - a follow-up
(10min)
2018: STAMPEDE M1 radiotherapy comparison results
Summary (6:33 min)
Full length (12:13 min)
2017: STAMPEDE abiraterone results
Summary (6:21 min)
Full version (12:48 min)
2015: STAMPEDE docetaxel and zoledronic acid results
Summary for health workers (14:08 min)
Summary for patients (14:56 min)
Type of study
Randomised trial
Contact details
Who is funding the study?
The trial is mainly funded by the charity Cancer Research UK with extra support from four pharmaceutical companies: Pfizer, Sanofi-Aventis, Novartis, Janssen, Astellas and Clovis.
When is it taking place?
The first STAMPEDE arms opened in 2005. Recruitment closed at the end of March 2023, and no further arms will be added to the study. Follow-up of enrolled patients continues.
Where is it taking place?
Follow up continues at participating hospitals in the UK. The participating Swiss sites are now closed and are no longer involved in the follow up or recruitment of participants.
Who is included?
Men with newly diagnosed advanced prostate cancer, or with relapsing prostate cancer.